Skip to Main Content

Paper Details

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma.
Blood Cancer J
16
2018
GI intolerance, Ixazomib, NDMM, Patients, bortezomib, cyclophosphamide, cytopenias, dexamethasone, fatigue, ixazomib, multiple myeloma, patients

Datasets

Release 1.2